GSK

Asexual blood stages

GSK484

Translational

-

Preclinical

Product vision	Uncomplicated malaria treatment and resistance management
MOA	Novel and unknown
Key features	Fast killing in vitro and in vivo No resistant mutants identified Low predicted dose (100 mg) and 200 h predicted half-life
Challenges	Human phamacokinetic prediction for low clearance compounds Synthetic route: Palladium used in two chemical steps
Status	Metabolite identification ongoing to confirm human PK prediction Photosafety study ongoing
Next milestone	Completion of Good Laboratory Practice (GLP) toxicology programme
Previously	Also known as MMV1793192
Project Director	Dr Zaira Rizopoulos